AGC Biologics Appoints GM at Boulder Facility

p.p1 {margin: 0.0px 0.0px 8.0px 0.0px; font: 11.0px ‘Trebuchet MS’} span.s1 {letter-spacing: 0.0px}

AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), appointed Regina Choi-Rivera as the new General Manager of the company’s large-scale biopharmaceutical mammalian production facility in Boulder. She assumes executive oversight and leadership and will manage strategic development and facility operations.

“We’re incredibly excited that Ms. Choi-Rivera is joining AGC Biologics as the General Manager at our Boulder facility. She brings tremendous experience in both GMP manufacturing and project management,” said AGC Biologics Executive Vice President of U.S. Operations, J.D. Mowery. “Her breadth of knowledge and proven leadership give me great confidence that she is the right leader for our team, as well as our customers.”

Ms. Choi-Rivera has more than 25 years of experience in the biotech industry and joins AGC Biologics from Samsung Biologics where she most recently served as Vice President, Head of Drug Product Business Unit. Prior to that Ms. Choi-Rivera was Vice President, Head of the Drug Substance Contract Manufacturing Business unit. Prior to Samsung, she spent nearly a decade with Janssen Pharmaceutical’s R&D division, supporting pilot plant operations and managing outsourcing activities. 

AGC Biologics acquired the Boulder Facility in June 2020, giving the company additional capacity and a significantly larger production scale for mammalian-based projects in the U.S. The Boulder site houses two 20,000-liter stainless steel cell bioreactors and has more than twenty acres of undeveloped land for future expansion, including space for up to four more 20,000-liter bioreactors. The facility’s automation and capabilities make it well-suited for high volume commercial production and high titer antibody processes.